权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Extracranial Brain Stimulation Reduces Metabolic Insufficiency Through Enhanced Cerebral Blood Flow in CVN-AD Alzheimer's Model

颅外脑刺激通过增强 CVN-AD 阿尔茨海默病模型中的脑血流量来减少代谢不足

基本信息

批准号：
10338855
负责人：
DENNIS Alan TURNER
金额：
$ 37.31万
依托单位：
DUKE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-01 至 2026-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10338855
关键词：
Age Aging Alzheimer&apos s Disease Alzheimer&apos s disease model Animal Model Animals Behavioral Biological Markers Blood Vessels Blood capillaries Blood flow Brain Cells Cerebrovascular Circulation Chronic Clinical Clinical Trials Deep Brain Stimulation Degenerative Disorder Dementia Disease Disease Progression Disease model Dose Electric Stimulation Electrodes Electroencephalography Etiology Frequencies Genotype Glucose Goals Hippocampus (Brain)Human Hyperemia Impairment Lasers Lead Link Measures Memory Metabolic Metabolic Marker Metabolic stress Metabolism Modeling Motor Motor Activity Mus Nerve Degeneration Neurons Outcome Penetration Phenotype Physiological Physiology Radial Schedule Senile Plaques Sensory Signal Transduction Skin Stroke Surrogate Markers Syndrome Testing Time Translating aged aging brain appropriate dose awake base behavior test behavioral outcome cholinergic circadian conventional therapy cranium density disease phenotype dosage efficacious treatment electric field experimental study gene therapy hemodynamics improved improved functioning in vivo metabolomics mouse model neurological rehabilitation neuron loss neuropathology neuroregulation neurovascular neurovascular coupling pre-clinical predictive marker response spreading depression subcutaneous tau mutation tau phosphorylation tau-1 translational approach translational model translational potential voltage

项目摘要

Alzheimer's disease is a progressive degenerative disorder of unclear etiology and disease-modifying treatments remain elusive. However, there are abnormalities in substrate delivery to the brain, altered capillary reactivity, neurovascular coupling, and hemodynamic responsiveness to metabolic stress, such as low glucose or spreading depression, in both the disease and animal models (CVN-AD). Our hypothesis is that transcranial alternating current electrical stimulation (tACS) can improve metabolic insufficiency in a dose dependent and dynamic manner in the CVN-AD animal model of Alzheimer's disease, modulating disease progression and degeneration. We will apply tACS through skull mounted electrodes first on a scheduled approach, comparing 10 and 40 Hz stimulation to enhance cerebral blood flow and improve substrate delivery to the brain, assisted by Dr.'s Peterchev and Schmidt. Further, we will test behavioral outcomes to assess the effects of chronic, scheduled tACS and sham tACS over 4 weeks, starting at the critical points of degeneration at 12 and 24 weeks of age in the CVN-AD model, assessing outcome with probe trial errors on a Barnes maze, cerebral blood flow, measures of neurodegeneration. As a second goal we will develop dynamic, metabolic need-based tACS, using closed loop approaches. Surrogate physiological markers will include electrical recordings, glucose recordings, and EEG signals of activity to augment blood flow in a dynamic manner to improve immediate metabolic substrate supply and reduce degeneration. These experiments will establish the feasibility and parameters to translate into initial human studies using either semi-permanent skull mounted or temporary skin electrodes. Since current density and intracranial penetration of tACS is limited in humans various translational strategies will be devised to include dynamic biomarkers and appropriate stimulation levels through subcutaneous electrodes.

阿尔茨海默病是一种病因不明的进行性退行性疾病